ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Down 41.0% in November

ProPhase Labs, Inc. (NASDAQ:PRPH) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 144,900 shares, a decrease of 41.0% from the November 15th total of 245,700 shares. Based on an average daily trading volume, of 143,200 shares, the short-interest ratio is currently 1.0 days.

ProPhase Labs Trading Down 0.2 %

Shares of NASDAQ PRPH traded down $0.00 during trading hours on Thursday, hitting $0.64. The company’s stock had a trading volume of 175,706 shares, compared to its average volume of 70,289. ProPhase Labs has a 12 month low of $0.64 and a 12 month high of $7.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.33 and a current ratio of 1.47. The business has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $2.69. The stock has a market cap of $15.37 million, a price-to-earnings ratio of -0.51 and a beta of -0.32.

Institutional Trading of ProPhase Labs

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of ProPhase Labs by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after purchasing an additional 13,590 shares in the last quarter. HighTower Advisors LLC grew its holdings in shares of ProPhase Labs by 18.3% during the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after acquiring an additional 27,673 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of ProPhase Labs by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 618,763 shares of the company’s stock valued at $4,003,000 after purchasing an additional 9,416 shares during the period. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.